Nemolizumab, which targets the pruritogenic cytokine IL-31 [15, 16], has previously shown efficacy against moderate-to-severe pruritus associated with atopic dermatitis [16–19]; thus, this phase II study aimed to evaluate the efficacy and safety of nemolizumab in hemodialysis patients with UP. The gene discussed is IL31; the disease is Pruritus.